DEUP1

Summary

DEUP1 (deuterosome assembly protein 1, HGNC:26344) is a protein-coding gene on chromosome 11q21, encoding Deuterosome assembly protein 1 (Q05D60). Key structural component of the deuterosome, a structure that promotes de novo centriole amplification in multiciliated cells.

Enables identical protein binding activity. Predicted to be involved in centriole replication and de novo centriole assembly involved in multi-ciliated epithelial cell differentiation. Predicted to be located in cytoplasm and membrane. Predicted to be active in centriole and deuterosome.

Source: NCBI Gene 159989 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 21 total
• MANE Select transcript: NM_181645

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26344
Approved symbol	DEUP1
Name	deuterosome assembly protein 1
Location	11q21
Locus type	gene with protein product
Status	Approved
Aliases	FLJ25393
Ensembl gene	ENSG00000165325
Ensembl biotype	protein_coding
OMIM	617148
Entrez	159989

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 7 protein_coding, 2 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay, 1 non_stop_decay

ENST00000298050, ENST00000525646, ENST00000527307, ENST00000529909, ENST00000530053, ENST00000530273, ENST00000530862, ENST00000531448, ENST00000531792, ENST00000532819, ENST00000534747, ENST00000618031

RefSeq mRNA: 1 — MANE Select: NM_181645 NM_181645

CCDS: CCDS44707

Canonical transcript exons

ENST00000298050 — 14 exons

Exon	Start	End
ENSE00001092140	93371038	93371280
ENSE00001092142	93370073	93370186
ENSE00001092145	93385398	93385543
ENSE00001092146	93364160	93364294
ENSE00001092148	93389020	93389125
ENSE00001425947	93356948	93357043
ENSE00001532302	93330742	93330772
ENSE00002151028	93437543	93438470
ENSE00003461820	93396239	93396325
ENSE00003495111	93394459	93394656
ENSE00003545292	93332216	93332288
ENSE00003590657	93408231	93408427
ENSE00003671542	93415000	93415114
ENSE00003731127	93355371	93355542

Expression profiles

Bgee: expression breadth ubiquitous, 140 present calls, max score 92.09.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1388 / max 16.2391, expressed in 50 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
116223	0.1007	39
116222	0.0311	12
116221	0.0071	3

Top tissues by expression

218 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	92.09	gold quality
left testis	UBERON:0004533	88.86	gold quality
right testis	UBERON:0004534	88.39	gold quality
testis	UBERON:0000473	86.23	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.23	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.51	gold quality
right uterine tube	UBERON:0001302	81.21	gold quality
oviduct epithelium	UBERON:0004804	78.90	gold quality
islet of Langerhans	UBERON:0000006	74.51	gold quality
bronchial epithelial cell	CL:0002328	71.67	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	71.49	gold quality
bronchus	UBERON:0002185	70.26	gold quality
fallopian tube	UBERON:0003889	66.58	gold quality
mucosa of paranasal sinus	UBERON:0005030	65.72	gold quality
adenohypophysis	UBERON:0002196	64.07	gold quality
pituitary gland	UBERON:0000007	62.15	gold quality
buccal mucosa cell	CL:0002336	61.37	silver quality
lower lobe of lung	UBERON:0008949	61.36	silver quality
sural nerve	UBERON:0015488	59.86	silver quality
adrenal tissue	UBERON:0018303	59.54	gold quality
pancreas	UBERON:0001264	58.95	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	58.89	gold quality
right adrenal gland cortex	UBERON:0035827	58.59	gold quality
ventricular zone	UBERON:0003053	58.24	gold quality
spinal cord	UBERON:0002240	57.19	gold quality
nasal cavity mucosa	UBERON:0001826	55.75	gold quality
right adrenal gland	UBERON:0001233	55.59	gold quality
calcaneal tendon	UBERON:0003701	55.39	gold quality
hypothalamus	UBERON:0001898	54.58	gold quality
adrenal gland	UBERON:0002369	53.97	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	12.41
E-ANND-3	yes	5.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXN1

miRNA regulators (miRDB)

67 targeting DEUP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-8062	99.88	68.43	995
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-6505-5P	99.73	69.25	1595
HSA-MIR-1296-3P	99.72	64.04	636
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-29B-2-5P	99.67	68.98	1726
HSA-MIR-5093	99.67	69.26	2291
HSA-MIR-5700	99.64	69.88	2280

Literature-anchored findings (GeneRIF, showing 5)

• suggest that CCDC67 is a putative tumor suppressor gene that is silenced in gastric cancers by promoter CpG methylation and that it may play an important role in cell signaling and migration related to tumorigenesis (PMID:22610074)
• Loss of CCDC67 is associated with papillary thyroid carcinoma. (PMID:26716505)
• Single nucleotide polymorphism in CCDC67 gene is associated with Acute Renal Graft Rejection. (PMID:27272414)
• MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67. (PMID:31081096)
• E2F4’s cytoplasmic role in multiciliogenesis is mediated via an N-terminal domain that binds two components of the centriole replication machinery, Deup1 and SAS6. (PMID:34260288)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Deup1	ENSMUSG00000039977
rattus_norvegicus	Deup1	ENSRNOG00000061247

Paralogs (2): CCDC18 (ENSG00000122483), CEP63 (ENSG00000182923)

Protein

Protein identifiers

Deuterosome assembly protein 1 — Q05D60 (reviewed: Q05D60)

Alternative names: Coiled-coil domain-containing protein 67

All UniProt accessions (10): Q05D60, A0A087WVI3, A0A088AWP1, A0A0A0MTD8, A0A5H1ZRS0, E9PIY2, E9PLL9, E9PLX9, E9PMP4, E9PPB2

UniProt curated annotations — full annotation on UniProt →

Function. Key structural component of the deuterosome, a structure that promotes de novo centriole amplification in multiciliated cells. Deuterosome-mediated centriole amplification occurs in terminally differentiated multiciliated cells and can generate more than 100 centrioles. Probably sufficient for the specification and formation of the deuterosome inner core. Interacts with CEP152 and recruits PLK4 to activate centriole biogenesis.

Subunit / interactions. Interacts with CEP152; the interaction is mutually exclusive with CEP63.

Subcellular location. Cytoplasm.

Miscellaneous. CEP63 and DEUP1 paralogs are both involved in centriole amplification: while CEP63 mediates mother-centriole-dependent centriole duplication, DEUP1 mediates de novo centriole amplification in multiciliated cells.

Similarity. Belongs to the CEP63 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q05D60-1	1	yes
Q05D60-2	2

RefSeq proteins (1): NP_857596* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR031470	CEP63/Deup1_N	Domain
IPR057656	CEP63/Deup1_CC	Domain

Pfam: PF17045, PF25771

UniProt features (14 total): coiled-coil region 5, sequence variant 4, splice variant 2, chain 1, sequence conflict 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q05D60-F1	78.06	0.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 547

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 69 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, GOBP_EPITHELIUM_DEVELOPMENT, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_CENTRIOLE_ASSEMBLY, GOBP_ORGANELLE_ASSEMBLY, GOBP_COLUMNAR_CUBOIDAL_EPITHELIAL_CELL_DIFFERENTIATION, GOBP_CELL_PROJECTION_ORGANIZATION, SOX5_01, GOBP_CENTROSOME_DUPLICATION, GOCC_CENTRIOLE, GOBP_CELL_CYCLE_PROCESS, chr11q21, DODD_NASOPHARYNGEAL_CARCINOMA_DN, MIKKELSEN_ES_HCP_WITH_H3K27ME3, MIKKELSEN_MEF_HCP_WITH_H3_UNMETHYLATED

GO Biological Process (4): centriole replication (GO:0007099), cell projection organization (GO:0030030), de novo centriole assembly involved in multi-ciliated epithelial cell differentiation (GO:0098535), multi-ciliated epithelial cell differentiation (GO:1903251)

GO Molecular Function (2): identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (4): cytoplasm (GO:0005737), centriole (GO:0005814), deuterosome (GO:0098536), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
intracellular membraneless organelle	2
cell cycle process	1
centrosome duplication	1
centriole assembly	1
cellular component organization	1
de novo centriole assembly	1
multi-ciliated epithelial cell differentiation	1
columnar/cuboidal epithelial cell differentiation	1
protein binding	1
binding	1
intracellular anatomical structure	1
microtubule organizing center	1

Protein interactions and networks

STRING

672 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DEUP1	CCDC78	A2IDD5	744
DEUP1	CCNO	P22674	661
DEUP1	SASS6	Q6UVJ0	654
DEUP1	PLK4	O00444	653
DEUP1	TMEM135	Q86UB9	647
DEUP1	STIL	Q15468	644
DEUP1	MCIDAS	D6RGH6	638
DEUP1	CDC20B	Q86Y33	628
DEUP1	GMNC	A6NCL1	622
DEUP1	MAN2A1	Q16706	571
DEUP1	FOXJ1	Q92949	565
DEUP1	CEP152	O94986	540
DEUP1	CEP70	Q8NHQ1	496
DEUP1	CEP57	Q86XR8	486
DEUP1	CEP78	Q5JTW2	476

IntAct

225 interactions, top by confidence:

A	B	Type	Score
DEUP1	TXLNA	psi-mi:“MI:0915”(physical association)	0.720
DEUP1	DEUP1	psi-mi:“MI:0915”(physical association)	0.720
TXLNB	DEUP1	psi-mi:“MI:0915”(physical association)	0.720
DEUP1	EXOC5	psi-mi:“MI:0915”(physical association)	0.720
TXLNA	DEUP1	psi-mi:“MI:0915”(physical association)	0.720
DEUP1	TXLNB	psi-mi:“MI:0915”(physical association)	0.720
EXOC5	DEUP1	psi-mi:“MI:0915”(physical association)	0.720
DEUP1	DGCR6L	psi-mi:“MI:0915”(physical association)	0.720
DGCR6L	DEUP1	psi-mi:“MI:0915”(physical association)	0.720

BioGRID (116): CCDC67 (Two-hybrid), CCDC67 (Two-hybrid), CCDC67 (Two-hybrid), CCDC67 (Two-hybrid), CCDC67 (Two-hybrid), CCDC67 (Two-hybrid), CCDC67 (Two-hybrid), CCDC67 (Two-hybrid), CCDC67 (Two-hybrid), CCDC67 (Two-hybrid), CCDC67 (Two-hybrid), CCDC67 (Two-hybrid), CCDC67 (Two-hybrid), CCDC67 (Two-hybrid), CCDC67 (Two-hybrid)

ESM2 similar proteins: A0JMQ7, A0JMY4, A2AUM9, A2BDR7, A2BGP7, A6NI79, A6PWD2, A6QNP9, B1AJZ9, D3YV10, G9G127, O35550, O35551, O75330, O94986, P0CB05, Q05D60, Q0VFN8, Q0VFX2, Q15276, Q17QT2, Q3UPP8, Q498G2, Q4KLY0, Q4PJT6, Q4R703, Q4V7B0, Q5JU67, Q5NVN6, Q5U3A8, Q5U3Z6, Q5U4W1, Q5ZL12, Q66KE8, Q6DFC2, Q6DIS8, Q6IMY1, Q6NRC9, Q6P402, Q7M6Y5

Diamond homologs: B9V5F5, F7DP49, P0CB05, Q05D60, Q5U3Z6, Q7M6Y5, Q95JK1, Q3UPP8, Q4KLY0, Q4R703, Q5HZK9, Q5NVN6, Q6PGZ0, Q96MT8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

21 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	6
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2576 predictions. Top by Δscore:

Variant	Effect	Δscore
11:93330771:AGGTA:A	donor_loss	1.0000
11:93355362:A:AG	acceptor_gain	1.0000
11:93355362:AATT:A	acceptor_gain	1.0000
11:93355363:A:G	acceptor_gain	1.0000
11:93356943:TGCA:T	acceptor_loss	1.0000
11:93356945:CA:C	acceptor_loss	1.0000
11:93356946:A:G	acceptor_loss	1.0000
11:93356947:G:GC	acceptor_loss	1.0000
11:93356947:GGTA:G	acceptor_gain	1.0000
11:93357042:AAGTA:A	donor_loss	1.0000
11:93357043:AG:A	donor_loss	1.0000
11:93357044:G:GG	donor_gain	1.0000
11:93357044:GT:G	donor_loss	1.0000
11:93357045:T:A	donor_loss	1.0000
11:93364154:TTACA:T	acceptor_loss	1.0000
11:93364156:ACAG:A	acceptor_loss	1.0000
11:93364157:CAGTT:C	acceptor_loss	1.0000
11:93364158:A:AG	acceptor_gain	1.0000
11:93364159:G:GG	acceptor_gain	1.0000
11:93364159:G:T	acceptor_loss	1.0000
11:93364159:GT:G	acceptor_gain	1.0000
11:93364159:GTTTT:G	acceptor_gain	1.0000
11:93389015:TGTAG:T	acceptor_loss	1.0000
11:93389016:GTAGA:G	acceptor_loss	1.0000
11:93389018:A:AC	acceptor_loss	1.0000
11:93389018:A:AG	acceptor_gain	1.0000
11:93389019:G:GG	acceptor_gain	1.0000
11:93389019:GA:G	acceptor_gain	1.0000
11:93389019:GACTT:G	acceptor_gain	1.0000
11:93389123:AAGGT:A	donor_loss	1.0000

AlphaMissense

4050 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:93355403:T:C	L21S	0.999
11:93355447:T:A	W36R	0.999
11:93355447:T:C	W36R	0.999
11:93355449:G:C	W36C	0.998
11:93355449:G:T	W36C	0.998
11:93355394:T:C	L18P	0.997
11:93371180:T:C	L230P	0.996
11:93355394:T:A	L18H	0.995
11:93355412:A:C	Q24P	0.995
11:93355490:G:C	R50P	0.995
11:93355415:T:G	I25S	0.994
11:93355510:G:C	A57P	0.994
11:93356958:T:C	L71P	0.994
11:93355448:G:C	W36S	0.993
11:93437655:T:C	L584P	0.993
11:93355425:G:A	M28I	0.992
11:93355425:G:C	M28I	0.992
11:93355425:G:T	M28I	0.992
11:93357024:T:C	L93P	0.992
11:93357033:T:C	L96P	0.991
11:93371243:T:C	L251P	0.991
11:93371255:T:C	L255P	0.991
11:93355415:T:A	I25N	0.990
11:93364170:T:C	L103P	0.990
11:93394535:T:C	L373P	0.990
11:93437634:T:C	L577P	0.989
11:93355478:G:C	R46P	0.988
11:93355487:T:C	L49P	0.988
11:93394547:T:C	L377P	0.988
11:93371188:G:C	A233P	0.987

dbSNP variants (sampled 300 via entrez): RS1000013205 (11:93434589 C>T), RS1000023917 (11:93378979 C>T), RS1000056719 (11:93347906 AT>A,ATT), RS1000057269 (11:93332885 A>G), RS1000073142 (11:93393855 G>A), RS1000095535 (11:93419567 A>G), RS1000165584 (11:93375142 G>C), RS1000215728 (11:93358159 A>C), RS1000233744 (11:93372220 G>A,T), RS1000263536 (11:93405217 T>C), RS1000290875 (11:93407955 G>T), RS1000294970 (11:93365337 A>G), RS1000374350 (11:93401300 A>C), RS1000384344 (11:93434979 G>A), RS1000391022 (11:93364911 A>C)

Disease associations

OMIM: gene MIM:617148 | disease phenotypes: MIM:173900

GenCC curated gene-disease

Mondo (1): polycystic kidney disease (MONDO:0020642)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001444_21	Pulmonary function decline	4.000000e-06
GCST001762_792	Obesity-related traits	4.000000e-06
GCST002934_1	Zinc levels	2.000000e-07
GCST009202_6	Rostral middle frontal gyrus volume	8.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004713	FEV/FVC ratio

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D007690	Polycystic Kidney Diseases	C12.050.351.968.419.403.875; C12.200.777.419.403.875; C12.950.419.403.875; C16.131.077.717; C16.320.184.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
arsenite	increases methylation	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
CGP 52608	affects binding, increases reaction	1
Benzo(a)pyrene	increases methylation, affects methylation	1
Cadmium	increases abundance, increases expression	1
Folic Acid	decreases expression	1
Lipopolysaccharides	increases expression, affects response to substance, affects cotreatment	1
Tobacco Smoke Pollution	decreases expression	1
Triclosan	decreases expression	1
Valproic Acid	decreases methylation	1
Antirheumatic Agents	affects expression	1
Cadmium Chloride	increases abundance, increases expression	1

Clinical trials (associated diseases)

25 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02140814	PHASE2	COMPLETED	Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease
NCT02558595	PHASE2	COMPLETED	Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)
NCT02697617	PHASE2	COMPLETED	Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease
NCT02166489	PHASE1	COMPLETED	Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease
NCT01009957	PHASE2/PHASE3	TERMINATED	Everolimus on CKD Progression in ADPKD Patients
NCT01680250	PHASE2/PHASE3	UNKNOWN	Sirolimus for Massive Polycystic Liver
NCT00286156	PHASE1/PHASE2	COMPLETED	Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT03423810	EARLY_PHASE1	COMPLETED	Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients
NCT00792155	Not specified	RECRUITING	Polycystic Kidney Disease Data Repository
NCT01873235	Not specified	RECRUITING	PKD Clinical and Translational Core Study
NCT01931644	Not specified	COMPLETED	At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
NCT02142101	Not specified	COMPLETED	Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease
NCT02739750	Not specified	COMPLETED	Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease
NCT02936791	Not specified	RECRUITING	Early PKD Observational Cohort Study
NCT03726463	Not specified	UNKNOWN	Evaluation of Iliac and Renal Artery for Mechanism of Intracranial Aneurysm in ADPKD
NCT03889392	Not specified	COMPLETED	Evaluation of Nephrectomy Specimen for Intracranial Aneurysm Development in ADPKD
NCT03948113	Not specified	COMPLETED	Outcome of Autosomal Dominant Polycystic Kidney Disease Patients on Peritoneal Dialysis: a National Retrospective Study Based on Two French Registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network).
NCT04039061	Not specified	RECRUITING	ADPKD Patient Registry
NCT05215964	Not specified	UNKNOWN	The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
NCT06036992	Not specified	ACTIVE_NOT_RECRUITING	Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease
NCT06325644	Not specified	RECRUITING	Well-Formulated Ketogenic Diet Polycystic Kidney Disease
NCT06728228	Not specified	RECRUITING	Amnioinfusion for Fetal Renal Failure
NCT06841224	Not specified	ENROLLING_BY_INVITATION	The Factors Affecting IPP in Peritoneal Dialysis Patients with Polycystic Kidney Disease
NCT06867471	Not specified	RECRUITING	Effects of Exogenous Ketosis on Proteinuria and Renal Function
NCT07310641	Not specified	COMPLETED	Descriptive Analysis of Preimplantation Genetic Test (PGT)in Couples With Polycystic Kidney Disease (PKD). In the ADPKD Subgroup Evaluation of Outcomes and Complications Comparing Couples in Which the Father is Affected With Couples in Which the Mother is Affected